TY - JOUR
T1 - Fluoropyrimidines in the treatment of advanced neoplastic diseases
T2 - Role and advantages of UFT
AU - Del Vecchio, Michele
AU - Procopio, Giuseppe
AU - Cassata, Antonino
AU - Pozzi, Paola
AU - Busto, Giuseppina
AU - Celio, Luigi
AU - Bajetta, Emilio
PY - 1999/1
Y1 - 1999/1
N2 - The fluoropyrimidine antimetabolites were employed in a wide range of neoplastic diseases. In particular, 5-fluorouracil in association with other chemotherapeutic agents, or biochemical modulators was successfully used in the treatment of colorectal, gastric, breast, head and neck cancers. With this type of chemotherapy, a response rate ≤ 20% was obtained in gastrointestinal tumors, without a statistically significant impact on the overall survival. UFT is a combination of tegafur an uracil, which has the important advantage of an improved oral bioavailability, if we compare it with 5-fluorouracil. Uracil, avoiding the fluoropyrimidine degradation inside the tumor cells, increases the permanence of the metabolically active fluropyrimidine into the target cell, so having an improvement in the therapeutic activity. A very large spectrum of cancers were treated with this molecule. In particular, a response rate in the range of 20-40% was observed in the treatment of patients with metastatic colorectal cancer. Phase III trials are ongoing to evaluate the advantage on 5-FU of this new fluoropyrimidine in terms of clinical efficacy, and quality of life, considering the possibility to administer it orally.
AB - The fluoropyrimidine antimetabolites were employed in a wide range of neoplastic diseases. In particular, 5-fluorouracil in association with other chemotherapeutic agents, or biochemical modulators was successfully used in the treatment of colorectal, gastric, breast, head and neck cancers. With this type of chemotherapy, a response rate ≤ 20% was obtained in gastrointestinal tumors, without a statistically significant impact on the overall survival. UFT is a combination of tegafur an uracil, which has the important advantage of an improved oral bioavailability, if we compare it with 5-fluorouracil. Uracil, avoiding the fluoropyrimidine degradation inside the tumor cells, increases the permanence of the metabolically active fluropyrimidine into the target cell, so having an improvement in the therapeutic activity. A very large spectrum of cancers were treated with this molecule. In particular, a response rate in the range of 20-40% was observed in the treatment of patients with metastatic colorectal cancer. Phase III trials are ongoing to evaluate the advantage on 5-FU of this new fluoropyrimidine in terms of clinical efficacy, and quality of life, considering the possibility to administer it orally.
KW - Chemotherapy
KW - Colorectal cancer
KW - Fluoropyrimidines
UR - http://www.scopus.com/inward/record.url?scp=0032967648&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032967648&partnerID=8YFLogxK
M3 - Article
C2 - 10228489
AN - SCOPUS:0032967648
VL - 85
SP - 6
EP - 11
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 1
ER -